Clinical Research Directory
Browse clinical research sites, groups, and studies.
VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS
Sponsor: Navy General Hospital, Beijing
Summary
The goal of this phase 1/2 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS.
Official title: Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT for Elderly Patients With Higher-risk Myelodysplastic Syndromes
Key Details
Gender
All
Age Range
70 Years - Any
Study Type
INTERVENTIONAL
Enrollment
54
Start Date
2024-10-01
Completion Date
2030-09-01
Last Updated
2024-10-01
Healthy Volunteers
No
Conditions
Interventions
Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT
Patients were treated by VA Conditioning Regimen Allo-HSCT: Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7, donor stem cells infused from d9
Locations (1)
Navy General Hospital
Beijing, Beijing Municipality, China